We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Aalto Bio Launches Lysis Buffer Reagent for COVID-19 Testing

By LabMedica International staff writers
Posted on 02 May 2020
Aalto Bio Reagents Ltd. More...
(Dublin, Ireland), a supplier of critical raw materials and reagents for diagnostic tests, has launched its first RNA lysis buffer reagent for the pre-treatment of COVID 19 samples prior to testing.

This essential RNA Lysis buffer was produced by Aalto Bio due to the unavailability of similar reagents from other manufacturers in Europe. The volume of PCR tests being carried out for COVID-19 in Ireland as well as across the world is such that manufacturers simply cannot produce the volume of reagents required. In March 2020, Aalto Bio was contacted by Ireland's Health Service Executive (HSE) to see if the company could refocus its manufacturing and development capabilities to provide a RNA lysis buffer which would be used by hospitals and laboratories for COVID-19 testing. Within four weeks of being contacted, the first bulk order was shipped to the National Virus Reference Laboratory in UCD where most of Ireland's testing is being carried out.

“At Aalto Bio, we were happy to assist the HSE by producing this critical reagent to help alleviate some of the pressure that has been brought on the system by COVID-19. As the HSE continues to expand on its testing capabilities we expect the demand for critical raw material such as ours to grow, and we are prepared to offer our services when needed. As a wholly-owned Irish diagnostics company we are proud to be able to contribute towards the testing regime of COVID-19,” said Philip Noone, CEO, Aalto Bio Reagents.

Related Links:
Aalto Bio Reagents Ltd.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.